The latest News

Keep in touch with Cellestia.

cellestia-biotech-hero

The latest News

Keep in touch with Cellestia.

August 2017

Cellestia Enters Clinical Development for its Lead Compound CB-103

On August 11th Cellestia received full approval of its first-in-human Phase I – IIa clinical study with CB-103. See our Press Release.

June 2017

Scientific Meetings

Dr. Dirk Weber, Chief Medical Officer, has given an oral presentation at ICML 2017 on June 14th in Lugano. Cellestia Biotech has presented a poster at the EHA meeting on June 22nd–25th in Madrid.

June 2017

Management Team and Scientific Advisory Board extension

Gaudenz von Capeller has been appointed Chief Financial Officer. Professor Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research (ISREC), has been appointed as Chairman of the Scientific Advisory Board. See our Press Release.

Archive